Proceeds to fund clinical development of DIAG723, a first-in-class, disease-modifying therapy designed to correct the root cause of hereditary hemorrhagic telangiectasia and pulmonary arterial ...

Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration ...

NRG5051 is a first-in-class, orally bioavailable and CNS-penetrant next-generation inhibitor of the mitochondrial permeability transition pore (mPTP), acting through a novel undisclosed ...

Results from a Phase 1 study of GT-02287 in healthy volunteers demonstrated favorable safety and tolerability, plasma and CNS exposures in the projected therapeutic range, and target engagement with ...

The Phase 1b trial consisted of 24 patients with Parkinson’s disease, who received twice-weekly dosing of either HER-096 or placebo over a four-week period. The trial’s exploratory biomarker program ...

Dr Teja Kapoor recalls a formative case to illustrate how early recognition and multidisciplinary care are transforming the ...

Please provide your email address to receive an email when new articles are posted on . In this Healio video, David G. Standaert, MD, PhD, discusses a plenary session on disease-modifying trials in ...

FD4 to XingImaging and to ABLi Therapeutics to evaluate alpha-synuclein clearance from the brain in response to risvodetinib treatment SHANGHAI and ATLANTA and NEW HAVEN, Conn., Jan. 05, 2026 (GLOBE ...

Panelists discuss how earlier Alzheimer diagnosis enhances treatment planning and slows disease progression. Panelists ...

Please provide your email address to receive an email when new articles are posted on . Most patients with sickle cell disease are not using disease-modifying therapies. DMT use increased nearly 10% ...

Moving Biotech receives US FDA’s IND clearance for 4P004; strengthens its position as a leading innovator in disease-modifying osteoarthritis therapeutics: Lille, France Saturd ...